Taro Pharmaceutical Industries Ltd
F:TAL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Taro Pharmaceutical Industries Ltd
Operating Income
Taro Pharmaceutical Industries Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Taro Pharmaceutical Industries Ltd
F:TAL
|
Operating Income
$21.5m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
-26%
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Operating Income
$3.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-2%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Operating Income
-$10.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
I
|
InterCure Ltd
TASE:INCR
|
Operating Income
-₪49.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-74%
|
CAGR 10-Years
N/A
|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Operating Income
-$28m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-23%
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Operating Income
-$23.6m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-1%
|
|
Taro Pharmaceutical Industries Ltd
Glance View
In the often-underappreciated realm of generic pharmaceuticals, Taro Pharmaceutical Industries Ltd. has carved out a notable niche for itself. Founded in 1950 in Haifa, Israel, Taro's journey began with a focus on dermatological products, a specialism that continues to be at the heart of its operations. As generic drug prices have become increasingly competitive, Taro has distinguished itself through a robust portfolio that not only includes dermatology but also topical and oral medications across various therapeutic areas. The company's commitment to quality and cost-effective drug solutions stems from its strategic use of rigorous R&D efforts, channeling years of scientific expertise to bring affordable healthcare solutions to markets worldwide. In essence, Taro crafts a business model that balances operational efficiency with the nuanced complexities of pharmaceutical manufacturing and compliance. Underpinning Taro's business strategy is its prowess in generic drug manufacture, where it maximizes its revenue by capitalizing on patent expirations from mainstream pharmaceutical enterprises. With its deep understanding of regulatory frameworks and market dynamics, Taro adeptly navigates the intricate landscapes of the U.S. and international markets, leveraging its wide distribution network. The United States, being a major revenue driver, reflects Taro's prowess and its ability to quickly adapt to drug lifecycle shifts. Yet, Taro's success isn't solely attributed to scale but also to its meticulous cost management and operational synergies across its global facilities. This orchestration allows it to maintain competitive pricing while ensuring high-quality standards - a testament to its deep-rooted industry experience and strategic foresight.
See Also
What is Taro Pharmaceutical Industries Ltd's Operating Income?
Operating Income
21.5m
USD
Based on the financial report for Mar 31, 2024, Taro Pharmaceutical Industries Ltd's Operating Income amounts to 21.5m USD.
What is Taro Pharmaceutical Industries Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-26%
Over the last year, the Operating Income growth was 22%. The average annual Operating Income growth rates for Taro Pharmaceutical Industries Ltd have been -47% over the past three years , -41% over the past five years , and -26% over the past ten years .